REMEDi4ALL
@remedi4all.bsky.social
The European Platform for Medicines Repurposing. Funded by #HorizonEurope. remedi4all.org
💊 The REMEDi4ALL #Hackathon is underway in Montserrat! Following a visit to the Montserrat Monastery, participants have explored drug repurposing through REPURPOLIS and computational sessions. Next up: patient engagement, TPPs, eHTA and routes to market. #REMEDi4ALL
📄 A recent article from Inside Precision Medicine highlights REMEDi4ALL’s work with partners EURORDIS and Fraunhofer ITMP to support researchers and patient organisations across the repurposing pathway. 🔗 https://loom.ly/YVW3Zp8
Are you a patient representative curious about #DrugRepurposing? Join us at the #REMEDi4ALL Repurposing Bootcamp in Barcelona on 10-11 June 2027! A unique chance to learn, collaborate & share through lectures, workshops, and discussions. Apply now! 🔗 https://loom.ly/H2FxxGE
📢 New REMEDi4ALL publication! A new study presents a scalable drug repurposing approach that uses cell painting and morphological profiling to identify potential antiviral candidates to support future antiviral research and pandemic preparedness! 🔗 https://loom.ly/2CtU5YE
💊 The MOI-A study is investigating the potential of losartan as a treatment for older adolescents and adults living with this rare genetic bone disorder. As Alessandra Tolaccia of OIFE explains, the potential impact for adult patients is deeply personal. 👉 Learn more: https://loom.ly/uaJ_YgA
🌎 REMEDi4ALL Scientific Lead Don Lo contributed to an FDA-supported meeting on advancing drug repurposing opportunities towards regulatory approval and patient access. Don emphasised, “Translation is a team sport.” Progress requires coordinated expertise across sectors. 🔗https://loom.ly/EEind5M
Join the 'Medicines Reimagined' Forum, where enthusiasts and experts in drug repurposing unite! Connect, collaborate, share insights, and explore the challenges and successes in the #DrugRepurposing field. 👉 Join the dialogue today: https://remedi4all.org/stakeholder-forum
💊 Build your knowledge of drug repurposing with the REMEDi4ALL Digital Academy. This free online learning platform offers accessible, expert-led training for researchers, patient organisations, industry representatives. 👉 Start learning today: https://loom.ly/6FQD_TQ
🌍 On #MSDWorldDay, REMEDi4ALL stands with families affected by multiple sulfatase deficiency. Our demonstrator project is investigating whether tazarotene could be repurposed as a treatment for MSD, working closely with patient champion Alan Finglas. 👉Learn more: https://loom.ly/rfokBf8
💊 The MOI-A study, a REMEDi4ALL demonstrator project, is investigating the potential of losartan as a treatment for older adolescents and adults living with this rare genetic bone disorder. 👉 Learn more and find out how patients and families can get involved here: https://loom.ly/uaJ_YgA
🎥 Missed our webinar, Understanding the Value of Your Repurposed Medicine? You can now watch the full recording through the REMEDi4ALL Digital Academy. 🎓 Watch the webinar and start learning for free today: https://loom.ly/IeBJ9No
⏰ Final reminder! Join our webinar on Understanding the Value of Your Repurposed Medicine. Hear from Prof. Zoltán Kaló, Diana Kwast-Hoekstra and Dalma Hosszú on HTA, patient evidence and how early planning can strengthen drug repurposing. 👉 Register: https://loom.ly/P2DRFRA
Congratulations to Prof. Zoltán Kaló, co-founder of REMEDi4ALL partner Syreon Research Institute, on his appointment as Director General of Hungary’s National Health Insurance Fund. We look forward to continuing our collaboration through the REMEDi4ALL Policy Board. 🔗 https://loom.ly/oSxOKDM
💊 Repurposing of losartan for the treatment of Osteogenesis Imperfecta (OI) One of REMEDi4ALL’s demonstrator projects is running a clinical trial investigating whether losartan could offer benefits for adolescents and adults with OI. 👉 Learn how to get involved here: https://loom.ly/uaJ_YgA
📣 Join experts from the Syreon Research Institute for an insightful webinar exploring Health Technology Assessment (HTA), Early HTA, and the role of patient preference evidence in the development and evaluation of repurposed medicines. 👉 Register here: https://loom.ly/P2DRFRA
🎬 The #iDR26 highlight reel is here! Hear from participants as they reflect on the importance of bringing the global drug repurposing community together to exchange ideas and address the challenges of delivering repurposed medicines to the patients who need them. 🔗 More: https://loom.ly/IGWmuZQ
📝 Read our recent interview with REMEDi4ALL iDR26 poster first author Nikoleta Efthymiopoulou We spoke with her about the research and her experience presenting a poster exploring the prevalence and impact of repurposing across modern drug development. 🔗 Read more: https://loom.ly/52o4MUM
📣 Join experts from the Syreon Research Institute for an insightful webinar exploring Health Technology Assessment (HTA), Early HTA, and the role of patient preference evidence in the development and evaluation of repurposed medicines. 👉 Register here: https://loom.ly/P2DRFRA
💊 Repurposing of losartan for the treatment of Osteogenesis Imperfecta (OI) One of REMEDi4ALL’s demonstrator projects is running a clinical trial investigating whether losartan could offer benefits for adolescents and adults with OI. 👉 Learn how to get involved here: https://loom.ly/uaJ_YgA
📣 Join experts from the Syreon Research Institute for an insightful webinar exploring Health Technology Assessment (HTA), Early HTA, and the role of patient preference evidence in the development and evaluation of repurposed medicines. 👉 Register here: https://loom.ly/P2DRFRA
📚New REMEDi4ALL publication in Nature Reviews Drug Discovery looks at lessons from the EU repurposing pilot under STAMP — and how collaboration can help bridge the gap between research and approval. Read more➡️: https://loom.ly/UqrNI8k #DrugRepurposing #EUHealth #STAMP
📣 Join experts from the Syreon Research Institute for an insightful webinar exploring Health Technology Assessment (HTA), Early HTA, and the role of patient preference evidence in the development and evaluation of repurposed medicines. 👉 Register here: https://loom.ly/P2DRFRA
🧪 New publication from REMEDi4ALL researchers! Aligning methods across labs improves the reliability of drug repurposing for pancreatic cancer. Researchers confirmed a consistent effect of combining two existing medicines and enhanced chemotherapy response. 📖 Read more: https://loom.ly/IATG6dg
Are you a patient representative curious about #DrugRepurposing? Join us at the #REMEDi4ALL Repurposing Bootcamp in Paris, 2-3 November 2026! A unique chance to learn, collaborate & share through lectures, workshops, and discussions. Apply before 10 June here: 🔗 https://loom.ly/GVUxULs
🌐 Ahead of #iDR26, the REMEDi4ALL Funders Network met in Brussels, bringing together funders & policymakers. Discussions explored innovative #DrugRepurposing funding models, policy & regulatory conditions, and new tools supporting collaboration! 🔗Learn more: https://loom.ly/CxpCqYc
The Medicines Reimagined Stakeholder Forum brings together the diverse voices driving innovation in drug repurposing. Whether you're an experienced stakeholder or new to the field, this community is for you! 👉 Join the forum today: https://remedi4all.org/stakeholder-forum
Are you a patient representative curious about #DrugRepurposing? Join us at the #REMEDi4ALL Repurposing Bootcamp in Paris, 2-3 November 2026! A unique chance to learn, collaborate & share through lectures, workshops, and discussions. Apply now! 🔗 https://loom.ly/GVUxULs
Join the #REMEDi4ALL Drug Repurposing Bootcamp for Patient Representatives and lead the way in innovative treatment strategies! This training equips patient representatives with the essential knowledge and tools to drive innovation through drug repurposing Apply now! 🔗 https://loom.ly/GVUxULs
🔔 Last chance to apply for the REMEDi4ALL Hackathon! Applications close tomorrow (20 May, 23:59 CEST). Join multidisciplinary teams, get expert mentoring & work on impactful drug repurposing challenges. 📩 Apply now: https://loom.ly/lf9rypQ #DrugRepurposing #Hackathon